Clinical Efficacy and Safety of Memantine in Patients with Moderate to Severe Dementia.
- Author:
Inn Sook AHN
1
;
Tae Young HWANG
;
Seonwoo KIM
;
Ji Hea YUN
;
Misun SONG
;
Jaewon CHUNG
;
Doh Kwan KIM
Author Information
1. Clinical Research Center, Samsung Biomedical Research Institute, Seoul, Korea. paulkim@smc.samsung.co.kr
- Publication Type:Clinical Trial ; Original Article
- Keywords:
Dementia;
Memantine;
Clinical trial;
Korean version of Severe Impairment Battery(K-SIB)
- MeSH:
Cognition;
Dementia*;
Humans;
Memantine*;
Memory;
N-Methylaspartate
- From:Korean Journal of Psychopharmacology
2007;18(3):163-170
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: This study examined the efficacy and safety of memantine-an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist-in the treatment of moderate-to-severe dementia. METHODS: Forty-four patients with moderate-to-severe dementia received 20 mg of memantine daily for 24 weeks. The primary efficacy variable was measured by the Korean version of Severe Impairment Battery(K-SIB), and the secondary efficacy variables were measured using the Seoul-Activites of Daily Living(S-ADL) and Neuropsychiatric Inventory-Questionnaire(NPI-Q). Neuropsychological assessments were administrated at baseline, 12 weeks, and 24 weeks. Safety parameters were monitored. RESULTS: Of 44 patients recruited, 30 completed the study and 14 dropped out. Memantine-treated patients showed a therapeutic benefit in all efficacy variables ; the K-SIB, S-ADL, and NPI-Q total scores were not significantly different from baseline either at the endpoint(in the analysis of intention-to-treat, with the last observation carried forward, ITT-LOCF) or at week 24(in the analysis of observed cases, OC). The response rates, when "response" was defined as improved or unchanged in the K-SIB or the S-ADL scores, were 43.3 and 50%, respectively(in the analysis of OC). The responders showed significant improvement in the cognitive subdomain of memory function, praxis, visuospatial ability, and orienting to name. Memantine was shown to be tolerable and safe. CONCLUSIONS: Memantine treatment reduced or delayed clinical deterioration in cognition, function, and behavior in patients with moderate-to-severe dementia.
